James Dentzer, Curis CEO
November 11, 2022 06:50 AM EST
People

Curis shrinks head­count by 30% as ex­ecs place big­ger hopes on blood can­cer drug

Amber Tong

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Drug­mak­ers ex­ploit can­cer’s ‘lethal­i­ties’ to make next class of tar­get­ed ther­a­pies, with first re­sults for ...

Feng Zhang’s pro­tein nanopar­ti­cle start­up Aera Ther­a­peu­tics turns to lipid nanopar­ti­cles to jump­start its pipeline

The in­side sto­ry of how Sali­o­Gen, a start­up try­ing to wran­gle ‘jump­ing genes’ to make med­i­cines, fell apart

For­mer Tome CEO joins Flag­ship start­up; NGM Bio chief steps down as re­struc­tur­ing takes ef­fect

Miss­ing REMS de­lays Cy­to­ki­net­ic­s' heart drug PDU­FA, stock drops

sponsored

Rev­o­lu­tion­iz­ing obe­si­ty treat­ment: Could mi­to­chon­dria hold the key to un­lock­ing fat-spe­cif­ic weight loss?

A service from the Financial Times